{"id":453488,"date":"2021-03-09T07:33:12","date_gmt":"2021-03-09T12:33:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=453488"},"modified":"2021-03-09T07:33:12","modified_gmt":"2021-03-09T12:33:12","slug":"kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/","title":{"rendered":"KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET<\/em><br \/>\n        \n      <\/p>\n<p align=\"justify\">CELEBRATION, Fla., March  09, 2021  (GLOBE NEWSWIRE) &#8212; KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on\u00a0Thursday, March 11, 2021, at 4:30 p.m. ET, to discuss its corporate and financial results for the fourth quarter and full year 2020.<\/p>\n<p align=\"justify\">\n        <strong>Conference Call Information:<\/strong><\/p>\n<p>Interested participants and investors may access the conference call by dialing either:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">(866) 395-2480 (U.S.)<\/li>\n<li style=\"text-align:justify\">(678) 509-7538 (international)<\/li>\n<li style=\"text-align:justify\">Conference ID: 4085483\u00a0<\/li>\n<\/ul>\n<p align=\"justify\">An audio webcast with slide presentation will be accessible via the Investor Relations section of the Company\u2019s website,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EW4jvul1VTD_CCnClQzLbP5yWBS-pcen4RHn6d0FVB7xZl1iwcbxQ0OTxBrqn8EUUUFmrOOeTVzYoGUf-f2SOqg5t9Nqaka2DCihdOZHbzXwhtNB21GuheXs_Ql6Nu2x\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/investors.kempharm.com\/<\/a>. An archive of the webcast and presentation will be available for 90 days beginning at approximately\u00a05:30 p.m. ET, on\u00a0March 11, 2021.<\/p>\n<p align=\"justify\">\n        <strong>About AZSTARYS\u2122:<\/strong>\n      <\/p>\n<p align=\"justify\">AZSTARYS\u2122 is an FDA-approved, once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years or older. AZSTARYS consists of SDX, KemPharm\u2019s prodrug of d-methylphenidate (d-MPH), co-formulated with immediate release d-MPH.<\/p>\n<p align=\"justify\">The complete approved prescribing information for AZSTARYS may be downloaded in PDF format here: <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EW4jvul1VTD_CCnClQzLbGrq50Q2emYuyaY-aqbjwvA34UewPaKG1DWJvQGJ5Bni07O9jalo_mIG5KIMjJnsVo3GGT5Q-CfiZyudYDw2jN7NMbXHbszBJG766Cf4tyR1z8mujavfb6tw67ZqztArKqUCP_RoMTs0Uh_yGUTtj5nmf7Wf3I4q4OFSdtZu83x0l5FrEKDqG09pe9lHhaVfF8ZIlcEsWaLWDR-AjkdeQG9Ob62uzKn6QeX64PO169__\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/ml.globenewswire.com\/Resource\/Download\/4f63af91-9427-40da-b881-82a5e22a0315<\/a><\/p>\n<p align=\"justify\">\n        <strong>About KemPharm:<\/strong>\n      <\/p>\n<p align=\"justify\">KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT<sup>\u00ae<\/sup> (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT<sup>\u00ae<\/sup> technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm\u2019s product portfolio is highlighted by AZSTARYS\u2122, an FDA-approved, once-daily treatment for attention deficit hyperactivity disorder (ADHD) which is based on serdexmethylphenidate, (SDX), KemPharm\u2019s prodrug of d-methylphenidate (d-MPH). KemPharm is also advancing several clinical development candidates, including KP484 for the treatment of ADHD and KP879 for the treatment of Stimulant Use Disorder (SUD). AZSTARYS, KP484, and KP879 are all based on SDX. In addition, KemPharm has received FDA approval for APADAZ<sup>\u00ae<\/sup>, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. For more information on KemPharm and its pipeline of prodrug product candidates visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yV6fXC9AA3gJhTVGL2oLJmV8Ke2jPpDYGmtehlnhsG3w6nL0eeEu7O1yMI5g3ARRYPH1o5LeKP3l17-sl_fJLA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.kempharm.com<\/a> or connect with us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-FjtbjQjC-PTW1bHeOr3GP971EtkPNVmtcAb5sYEUhKZQX-6m3-6IZTsvXzrUxFwT2VV81_jY_tNMuCJZvUVaw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jjxaVTwY_yBg_V7GfxExa4-wBExhSKMzLNAIcElTiv7j9X4hRl0k1I40GURZ7aMPUuXg2om8kPA9W209js-a5ReeUPGpUsKFlip19TXD8OY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2waaYvtGvRLqll5hi7WnCtDnch0tGZR46knKLGDUCU3Kz3CtyIEaCLpPmEo5iNNhS83kZ5_uvlx5ibwVRL8SBg98-9MVHRCtk3PZVwqr6auIlTIMv2NvLAolJpFXheDD\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X9BNOOa4AFZ1_nDZ4_jHDdhJTbJJPQP7NVsj08SpJwl1m4wnIR3fciNCXbD8yOYL37IqLVfion04fBBLFrFGedFDQbzRyrSpqzWMeVoZPZ2qnhzvsGIHXmi2LRGm850w\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Caution Concerning Forward Looking Statements:<\/strong>\n      <\/p>\n<p align=\"justify\">This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation our proposed development and commercial timelines, and can be identified by the use of words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201ccontinue\u201d or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm\u2019s business are described in detail in KemPharm\u2019s Annual Report on Form 10-K for the year ended December 31, 2019, and KemPharm\u2019s other filings with the Securities and Exchange Commission. KemPharm is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p align=\"justify\">\n        <strong>KemPharm Contacts:<\/strong>\n      <\/p>\n<p align=\"justify\">Jason Rando \/ Maureen McEnroe<br \/>Tiberend Strategic Advisors, Inc.<br \/>(212) 375-2665 \/ 2664<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mxuWfs_tjqOMMLRUOKQcvlbmPAtvuCl7r629PMC-hzt16n2CQfckM8XAtzTz_ViOekLk9ol9OVQeuyRivmL6cmEFn8Gb_mhf9qHlGzlPVMU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">jrando@tiberend.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ncMO9ocg_GmQGTs-kAEljxK41j4S4utDsmH_sCBNNnNWPmcdXso5q-s6vj1eTjs7u3Hn3bGgwE_1XTlJBJih_A0qMXeeRfriO5CwlV1crl0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mmcenroe@tiberend.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYzOCM0MDU0Njg4IzIwMTc3NTc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/afa38eb7-5302-448c-b152-5b8bdcfc4baf\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET CELEBRATION, Fla., March 09, 2021 (GLOBE NEWSWIRE) &#8212; KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on\u00a0Thursday, March 11, 2021, at 4:30 p.m. ET, to discuss its corporate and financial results for the fourth quarter and full year 2020. Conference Call Information: Interested participants and investors may access the conference call by dialing either: (866) 395-2480 (U.S.) (678) 509-7538 (international) Conference ID: 4085483\u00a0 An audio webcast with slide presentation will be accessible via the Investor Relations section of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-453488","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET CELEBRATION, Fla., March 09, 2021 (GLOBE NEWSWIRE) &#8212; KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on\u00a0Thursday, March 11, 2021, at 4:30 p.m. ET, to discuss its corporate and financial results for the fourth quarter and full year 2020. Conference Call Information: Interested participants and investors may access the conference call by dialing either: (866) 395-2480 (U.S.) (678) 509-7538 (international) Conference ID: 4085483\u00a0 An audio webcast with slide presentation will be accessible via the Investor Relations section of the &hellip; Continue reading &quot;KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T12:33:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYzOCM0MDU0Njg4IzIwMTc3NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results\",\"datePublished\":\"2021-03-09T12:33:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\\\/\"},\"wordCount\":610,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjYzOCM0MDU0Njg4IzIwMTc3NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\\\/\",\"name\":\"KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjYzOCM0MDU0Njg4IzIwMTc3NTc=\",\"datePublished\":\"2021-03-09T12:33:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjYzOCM0MDU0Njg4IzIwMTc3NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjYzOCM0MDU0Njg4IzIwMTc3NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results - Market Newsdesk","og_description":"Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET CELEBRATION, Fla., March 09, 2021 (GLOBE NEWSWIRE) &#8212; KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on\u00a0Thursday, March 11, 2021, at 4:30 p.m. ET, to discuss its corporate and financial results for the fourth quarter and full year 2020. Conference Call Information: Interested participants and investors may access the conference call by dialing either: (866) 395-2480 (U.S.) (678) 509-7538 (international) Conference ID: 4085483\u00a0 An audio webcast with slide presentation will be accessible via the Investor Relations section of the &hellip; Continue reading \"KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-09T12:33:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYzOCM0MDU0Njg4IzIwMTc3NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results","datePublished":"2021-03-09T12:33:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/"},"wordCount":610,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYzOCM0MDU0Njg4IzIwMTc3NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/","name":"KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYzOCM0MDU0Njg4IzIwMTc3NTc=","datePublished":"2021-03-09T12:33:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYzOCM0MDU0Njg4IzIwMTc3NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYzOCM0MDU0Njg4IzIwMTc3NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-to-report-fourth-quarter-and-full-year-2020-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=453488"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453488\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=453488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=453488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=453488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}